In a landmark decision, India’s intellectual property office on Monday allowed Hyderabad-based Natco Pharma Ltd to make and sell a copycat version of German drug maker Bayer AG’s patented cancer treatment Nexavar. It’s the first time that an Indian company has been granted the so-called compulsory licence to market a generic version of a patented drug. The drug, patented by Bayer in India in 2008, is used in the treatment of...

-The Economic Times The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision.  The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...

Decades after peasants’ networks have advocated for a new legal instrument to protect the rights of small farmers to land, seeds, traditional agricultural knowledge and freedom to determine the prices of their production, the United Nations Human Rights Council (UNHRC) may decide to start drafting a declaration on peasants’ rights next week. "The idea of an international declaration on peasants' rights comes from our (base) because many small farmers don’t have...

As non-governmental organisations question the relevance of the World Water Forum being held here this week and slam its "corporate" nature, the United Nations says that a coordinated approach to managing and allocating water is critical. The fourth edition of the triennial World Water Development Report (WWDR), which brings together the work of 28 U.N.-Water members and partners is being officially launched Monday at the Forum. It stresses that water "underpins...

-The Economist   Nuclear power will not go away, but its role may never be more than marginal, says Oliver Morton THE LIGHTS ARE not going off all over Japan, but the nuclear power plants are. Of the 54 reactors in those plants, with a combined capacity of 47.5 gigawatts (GW, a thousand megawatts), only two are operating today. A good dozen are unlikely ever to reopen: six at Fukushima Dai-ichi, which suffered...